Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

9.7%

3 terminated/withdrawn out of 31 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

0%

0 of 21 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
10(47.6%)
Phase 2
8(38.1%)
Phase 3
3(14.3%)
21Total
Phase 1(10)
Phase 2(8)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials
NCT04612465Phase 3Active Not Recruiting

Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula

Role: lead

NCT04569409Phase 3Completed

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.

Role: lead

NCT06539429Phase 1Active Not Recruiting

Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L

Role: lead

NCT03754465Phase 2Completed

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

Role: lead

NCT06141811Recruiting

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

Role: lead

NCT05157958Phase 2Recruiting

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

Role: lead

NCT02619851Phase 2Completed

A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects

Role: lead

NCT03183804Completed

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-201 Clinical Trial

Role: lead

NCT03370874Phase 3Completed

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.

Role: lead

NCT04590703Completed

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-301 Clinical Trial

Role: lead

NCT03183648Completed

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-201 Clinical Trial

Role: lead

NCT03183661Recruiting

A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

Role: lead

NCT02580617Phase 1Unknown

A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease

Role: lead

NCT02579369Phase 1Completed

Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Role: lead

NCT03183934Completed

A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial

Role: lead

NCT01440699Phase 1Completed

Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula

Role: lead

NCT04497805Phase 2Unknown

Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers

Role: lead

NCT03183726Completed

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial

Role: lead

NCT03183622Completed

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial

Role: lead

NCT02619877Phase 2Completed

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers

Role: lead